Related references
Note: Only part of the references are listed.BCR-ABLT315I transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine:: a new therapeutic challenge?
L. Legros et al.
LEUKEMIA (2007)
Interferon-α or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation
Hugues de Lavallade et al.
BLOOD (2007)
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy
Alfonso Quintas-Cardama et al.
CANCER (2007)
Homoharringtonine induces apoptosis and growth arrest in human myeloma cells
Yin-Jun Lou et al.
LEUKEMIA & LYMPHOMA (2007)
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
Brian J. Druker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia
Rong Chen et al.
CANCER RESEARCH (2006)
A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemia
V. Levy et al.
BRITISH JOURNAL OF CANCER (2006)
Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells
RP Tang et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib
D Marin et al.
CANCER (2005)
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
E Weisberg et al.
CANCER CELL (2005)
Overriding imatinib resistance with a novel ABL kinase inhibitor
NP Shah et al.
SCIENCE (2004)
Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP)
YJ Lou et al.
AMERICAN JOURNAL OF HEMATOLOGY (2004)
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase
S O'Brien et al.
CANCER (2003)
Molecular modes of action of artesunate in tumor cell lines
T Efferth et al.
MOLECULAR PHARMACOLOGY (2003)
Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs
AJ Tipping et al.
LEUKEMIA (2002)
In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells
B Scappini et al.
CANCER (2002)
Simultaneous homoharringtonine and interferon-α in the treatment of patients with chronic-phase chronic myelogenous leukemia
S O'Brien et al.
CANCER (2002)
Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
ME Gorre et al.
SCIENCE (2001)
In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents
Y Kano et al.
BLOOD (2001)
Share Paper
